Surrozen, Inc.

Surrozen, Inc. is a biotechnology company specializing in the discovery and development of drug candidates that selectively modulate the Wnt pathway for tissue repair and regeneration. The company's focus is on developing tissue-specific antibodies to engage the body's biological repair mechanisms, with potential applications across various disease areas such as intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its pipeline includes SZN-043, which stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis, and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to specific Frizzled and LRP receptors highly expressed in intestinal crypts.